NASDAQ · YI

111, Inc.. American

$3.80 -$0.11 (-2.81%) 1D Market open

Key Metrics

$33.43M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow $16.40M
Beta · 1Y 0.25
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    From its Feb 23 high, the share price fell 57%.

    Peak close $8.38 on Feb 23; trough close $3.63 on Jul 17. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -57%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 22
    The stock moved -16.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 22
  • Jan 30
    The stock moved +41.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jan 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$33.43M
Enterprise value
Shares outstanding8.8M
52-wk range$2.60 – $11.17
Avg volume · 20D28.0K
Net cash
Book value / share$-11.42
ExchangeNASDAQ
About 111, Inc.. American
IPO dateSep 12, 2018
Employees1063

111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added se…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF2.04
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio1.09
Quick ratio0.58
Debt / equity
Debt / EBITDA
Net cash
Working capital$24.48M

Cash Flow · TTM

Operating CF $17.04M
Capex −$636.00K
Free cash flow $16.40M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings